Tetraphase Pharmaceuticals’ (NASDAQ:TTPH) Hold Rating Reiterated at Needham & Company LLC
Several other equities analysts have also weighed in on the company. BMO Capital Markets restated an outperform rating and issued a $13.00 price target (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, July 26th. Stifel Nicolaus upgraded Tetraphase Pharmaceuticals from a hold rating to a buy rating and lifted their price target for the company from $8.00 to $15.00 in a research note on Wednesday, July 26th. HC Wainwright assumed coverage on Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They issued a buy rating and a $15.00 price target for the company. Finally, Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, July 6th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Tetraphase Pharmaceuticals has a consensus rating of Buy and a consensus price target of $10.25.
Shares of Tetraphase Pharmaceuticals (TTPH) opened at 6.48 on Thursday. The company’s 50 day moving average price is $7.45 and its 200 day moving average price is $6.85. The stock’s market cap is $245.95 million. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.46 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. Tetraphase Pharmaceuticals’s revenue for the quarter was down 24.5% on a year-over-year basis. On average, analysts anticipate that Tetraphase Pharmaceuticals will post ($2.65) earnings per share for the current year.
WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-nasdaqttph-hold-rating-reiterated-at-needham-company-llc/1464121.html.
A number of large investors have recently bought and sold shares of TTPH. Trexquant Investment LP purchased a new stake in Tetraphase Pharmaceuticals during the first quarter valued at approximately $265,000. Parametric Portfolio Associates LLC raised its stake in Tetraphase Pharmaceuticals by 22.5% in the first quarter. Parametric Portfolio Associates LLC now owns 62,423 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 11,458 shares during the period. Wade G W & Inc. purchased a new stake in Tetraphase Pharmaceuticals during the first quarter valued at approximately $138,000. Teza Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,281 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Tetraphase Pharmaceuticals by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after buying an additional 6,114 shares during the period. Institutional investors own 45.48% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.